收费全文 | 416篇 |
免费 | 26篇 |
国内免费 | 1篇 |
耳鼻咽喉 | 1篇 |
儿科学 | 8篇 |
妇产科学 | 19篇 |
基础医学 | 50篇 |
口腔科学 | 4篇 |
临床医学 | 54篇 |
内科学 | 104篇 |
皮肤病学 | 15篇 |
神经病学 | 20篇 |
特种医学 | 11篇 |
外科学 | 38篇 |
综合类 | 13篇 |
预防医学 | 41篇 |
眼科学 | 13篇 |
药学 | 30篇 |
中国医学 | 2篇 |
肿瘤学 | 20篇 |
2023年 | 5篇 |
2022年 | 15篇 |
2021年 | 20篇 |
2020年 | 12篇 |
2019年 | 18篇 |
2018年 | 21篇 |
2017年 | 11篇 |
2016年 | 13篇 |
2015年 | 11篇 |
2014年 | 13篇 |
2013年 | 25篇 |
2012年 | 38篇 |
2011年 | 38篇 |
2010年 | 23篇 |
2009年 | 16篇 |
2008年 | 23篇 |
2007年 | 34篇 |
2006年 | 29篇 |
2005年 | 22篇 |
2004年 | 16篇 |
2003年 | 15篇 |
2002年 | 6篇 |
2001年 | 5篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1992年 | 1篇 |
1990年 | 3篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1976年 | 1篇 |
Background
Symptoms account for more than 400 million clinic visits annually in the USA. The SPADE symptoms (sleep, pain, anxiety, depression, and low energy/fatigue) are particularly prevalent and undertreated.Objective
To assess the effectiveness of providing PROMIS (Patient-Reported Outcome Measure Information System) symptom scores to clinicians on symptom outcomes.Design
Randomized clinical trial conducted from March 2015 through May 2016 in general internal medicine and family practice clinics in an academic healthcare system.Participants
Primary care patients who screened positive for at least one SPADE symptom.Interventions
After completing the PROMIS symptom measures electronically immediately prior to their visit, the 300 study participants were randomized to a feedback group in which their clinician received a visual display of symptom scores or a control group in which scores were not provided to clinicians.Main Measures
The primary outcome was the 3-month change in composite SPADE score. Secondary outcomes were individual symptom scores, symptom documentation in the clinic note, symptom-specific clinician actions, and patient satisfaction.Key Results
Most patients (84%) had multiple clinically significant (T-score?≥?55) SPADE symptoms. Both groups demonstrated moderate symptom improvement with a non-significant trend favoring the feedback compared to control group (between-group difference in composite T-score improvement, 1.1; P?=?0.17). Symptoms present at baseline resolved at 3-month follow-up only one third of the time, and patients frequently still desired treatment. Except for pain, clinically significant symptoms were documented less than half the time. Neither symptom documentation, symptom-specific clinician actions, nor patient satisfaction differed between treatment arms. Predictors of greater symptom improvement included female sex, black race, fewer medical conditions, and receiving care in a family medicine clinic.Conclusions
Simple feedback of symptom scores to primary care clinicians in the absence of additional systems support or incentives is not superior to usual care in improving symptom outcomes.Trial Registration
clinicaltrials.gov identifier: NCT02383862.Methods: Outcomes of labor after induction in pregnant women at term were compared in a randomized trial. Women were assigned to having their membranes “swept” or “not swept” at the initiation of labor induction.
Results: We recruited a total of 870 women of which 70 were excluded. There were 400 nullipara (Group A) [198 “swept”, 202 “not swept”] and 400 multiparas (Group B) (201 “swept” and 199 “not swept”]. Among group A who received intravaginal prostaglandin (PG) E2, those who had simultaneous sweeping had significantly shorter mean induction-labor interval (12.9?±?1.3 versus 16.2?±?1.1 hours, p?=?0.046), lower mean dose of oxytocin (6.6?±?0.6 versus 10.11?±?1.4?mU/minute, p?=?0.01), and increased normal delivery rates (vaginal delivery 82.8% versus 58.6%, p?=?0.01). Sweeping also had a favorable effect on nulliparas who had ARM and received oxytocin alone (mean induction-labor interval 5.9?±?2.9 versus 10.9?±?2.6 hours p?=?0.04, mean maximum dose of oxytocin 9.8?±?1.1 versus 15.2?±?1.1?mU/min, p?=?0.01). These results were restricted to women with unfavorable cervix in Group A those who had membrane sweeping.
Conclusion: Membrane sweeping, has beneficial effects on labor and delivery, which is limited to nulliparas with unfavorable cervix requiring PGE2 or Oxytocin alone. 相似文献